Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) EBIT: 2023-2025

Historic EBIT for Inhibrx Biosciences (INBX) over the last 3 years, with Sep 2025 value amounting to -$33.8 million.

  • Inhibrx Biosciences' EBIT rose 27.75% to -$33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$154.0 million, marking a year-over-year increase of 58.35%. This contributed to the annual value of -$331.4 million for FY2024, which is 51.19% down from last year.
  • According to the latest figures from Q3 2025, Inhibrx Biosciences' EBIT is -$33.8 million, which was down 23.45% from -$27.4 million recorded in Q2 2025.
  • Over the past 5 years, Inhibrx Biosciences' EBIT peaked at -$27.4 million during Q2 2025, and registered a low of -$160.9 million during Q2 2024.
  • Over the past 3 years, Inhibrx Biosciences' median EBIT value was -$46.3 million (recorded in 2023), while the average stood at -$61.3 million.
  • Per our database at Business Quant, Inhibrx Biosciences' EBIT plummeted by 267.63% in 2024 and then surged by 82.98% in 2025.
  • Quarterly analysis of 3 years shows Inhibrx Biosciences' EBIT stood at -$88.3 million in 2023, then soared by 43.45% to -$49.9 million in 2024, then climbed by 27.75% to -$33.8 million in 2025.
  • Its EBIT stands at -$33.8 million for Q3 2025, versus -$27.4 million for Q2 2025 and -$42.9 million for Q1 2025.